Compounds > 1-(2,3-methylenedioxyphenyl)-2-aminopropane
Page last updated: 2024-12-08
1-(2,3-methylenedioxyphenyl)-2-aminopropane
Description
1-(2,3-methylenedioxyphenyl)-2-aminopropane is the chemical name for **3,4-methylenedioxymethamphetamine (MDMA)**, commonly known as **ecstasy** or **molly**.
Here's why it's important for research:
**1. Understanding its effects:**
* **Neurological effects:** MDMA is a potent stimulant and hallucinogen that affects the central nervous system, particularly the release of serotonin, dopamine, and norepinephrine. Research focuses on how it alters brain function, leading to feelings of euphoria, empathy, and altered perceptions.
* **Therapeutic potential:** Research explores MDMA-assisted therapy for conditions like PTSD, anxiety, and addiction. Preliminary studies show promise in treating these conditions, though further investigation is needed.
* **Side effects and risks:** Studies investigate the potential dangers of MDMA use, including addiction, cardiovascular problems, and neurotoxicity. Understanding these risks is crucial for public health and safety.
**2. Investigating its mechanisms:**
* **Pharmacokinetics:** Research investigates how MDMA is absorbed, distributed, metabolized, and excreted by the body. This knowledge is essential for understanding its effects and developing safer forms of the drug.
* **Neurobiology:** Studies examine the specific neuronal pathways and receptors affected by MDMA, helping to elucidate its complex mechanisms of action in the brain.
**3. Developing new therapies:**
* **New drug development:** Research explores the potential of MDMA analogs with reduced side effects and enhanced therapeutic potential.
* **Drug delivery systems:** Studies investigate different methods to deliver MDMA more effectively and safely for therapeutic use.
**Important Note:** Research on MDMA is complex and often controversial. While it holds potential for therapeutic applications, its recreational use carries significant risks. It's crucial to conduct research ethically and responsibly, ensuring the safety of participants and the public.
**Disclaimer:** I am an AI chatbot and cannot provide medical advice. If you have questions about MDMA or any other drug, please consult a healthcare professional.
1-(2,3-methylenedioxyphenyl)-2-aminopropane: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 152655 |
SCHEMBL ID | 394419 |
MeSH ID | M0127814 |
Synonyms (22)
Synonym |
2,3-methylenedioxyamphetamine |
1-(1,3-benzodioxol-4-yl)propan-2-amine |
AKOS006291195 |
1,3-benzodioxole-4-ethanamine, alpha-methyl- |
unii-6409s541pa |
6409s541pa , |
1-(2,3-methylenedioxyphenyl)-2-aminopropane |
2,3-mda |
23693-17-6 |
2,3-methylenedioxyphenylisopropylamine |
1-(2h-1,3-benzodioxol-4-yl)propan-2-amine |
1,3-benzodioxole-4-ethanamine, .alpha.-methyl- |
2,3-mda [nflis-drug] |
5-methylenedioxyamphetamine |
SCHEMBL394419 |
Q4596763 |
alpha-methyl-1,3-benzodioxole-4-ethanamine |
DTXSID00946494 |
benzo fury |
PD048358 |
1-(1,3-dioxaindan-4-yl)propan-2-amine |
EN300-6512522 |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.64
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.64 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.59 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |